Skip to main content

Table 7 Univariate analysis of local recurrence in patients treated with perioperative denosumab and curettage for GCTBa (n = 40)

From: Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study

Comparison of factors

No. of local recurrence (%)

Univariate analysis

p valueb

All patients (n = 40)

Timing of denosumab

 Preoperative only

6/21 (28.6%)

p = 0.719

 Postoperative only

2/9 (22.2%)

Timing of denosumab

 Both pre- and postoperative

0/10 (0.0%)

p = 0.068

 Pre- or postoperative only

8/30 (26.7%)

Preoperative (n = 31)

Times of denosumab administration

 5>

5/7 (71.4%)

p < 0.001

 5≦

1/24 (4.2%)

 Timing of denosumab

 Preoperative only

6/21 (28.6%)

p = 0.060

 Both pre- and postoperative

0/10 (18.9%)

Postoperative (n = 19)

 Times of denosumab administration

 5>

0/7 (0.0%)

p = 0.253

 5≦

2/12 (16.7%)

Embolization before surgery

 Postoperative only

2/9 (22.2%)

p = 0.115

 Both pre- and postoperative

0/10 (0.0%)

  1. aGCTB, giant cell tumor of bone
  2. bChi-square test